Compare Domino's Pizza, Inc. (DPZ) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Domino's Pizza, Inc. trades at $297.01 (market cap $9.74B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Domino's Pizza, Inc. is far larger — about 10× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Domino's Pizza, Inc. pays a 2.69% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Domino's Pizza, Inc. for 106 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| DPZ | MRVI | |
|---|---|---|
Market Cap | $9.74B | $972.90M |
Volume | 2,053,142 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $438.42 | $9.00 |
52-Week Low | $282.89 | $2.83 |
Typical Hold Time | 106 Days | 0 Days |
Enterprise Value | $14.63B | $1.08B |
Dividend Yield | 2.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $295.89, down 4.83% with mixed technical signals but strong fundamentals. The stock shows a bullish overall technical signal despite recent price weakness, while fundamentals reveal consistent revenue growth to $4.94 billion in 2025 and healthy net margins of 11.86%. Recent earnings show improvement with a Q3 2026 beat after three consecutive misses, though the company faces high debt levels and flat dividend growth.
The outlook remains cautiously optimistic with a $368 consensus price target representing 24% upside potential. Key opportunities include sustained profitability and market leadership, while risks center on high leverage and competitive pressures. Analyst sentiment leans bullish with 50% buy ratings, but investors should monitor debt management and same-store sales trends.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
